Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 8/20 | 0.43 |
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452076 | 0.92 | TP53 (0.47) | TP53THRBMAPTPOLBSHMT2 | |
| SCHEMBL5261470 | 0.92 | TP53 (0.41) | TP53THRBMEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL6311494 | 0.91 | TP53 (0.46) | TP53THRBMAPTPOLBSHMT2 | |
| SCHEMBL4446709 | 0.86 | SLC9A1 (0.51) | TP53THRBMEN1KMT2AMAPT | |
| SCHEMBL4452480 | 0.86 | SMN1; SMN2 (0.40) | TP53THRBMEN1KMT2AMAPT | |
| SCHEMBL4450205 | 0.85 | SLC9A1 (0.48) | TP53THRBMEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL6319607 | 0.85 | SLC9A1 (0.50) | TP53THRBMEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL6311618 | 0.85 | SMN1; SMN2 (0.41) | TP53THRBMEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL6314755 | 0.85 | SLC9A1 (0.48) | TP53THRBMEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL6321489 | 0.84 | SLC9A1 (0.47) | TP53THRBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | TP53 4547/4885THRB 271/4885MEN1 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.